Daniel R Goulet
Overview
Explore the profile of Daniel R Goulet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
253
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bent E, Millan-Barea L, Zhuang I, Goulet D, Frose J, Hemann M
Nat Commun
. 2021 Oct;
12(1):6218.
PMID: 34711820
Cytotoxic chemotherapeutics primarily function through DNA damage-induced tumor cell apoptosis, although the inflammation provoked by these agents can stimulate anti-cancer immune responses. The mechanisms that control these distinct effects and...
2.
Angus S, Stuhlmiller T, Mehta G, Bevill S, Goulet D, Olivares-Quintero J, et al.
NPJ Breast Cancer
. 2021 May;
7(1):51.
PMID: 33980863
Inhibition of the HER2/ERBB2 receptor is a keystone to treating HER2-positive malignancies, particularly breast cancer, but a significant fraction of HER2-positive (HER2+) breast cancers recur or fail to respond. Anti-HER2...
3.
Goulet D, Foster 2nd J, Zawistowski J, Bevill S, Noel M, Olivares-Quintero J, et al.
Mol Cancer Res
. 2020 Aug;
18(11):1685-1698.
PMID: 32753473
Triple-negative breast cancers contain a spectrum of epithelial and mesenchymal phenotypes. SUM-229PE cells represent a model for this heterogeneity, maintaining both epithelial and mesenchymal subpopulations that are genomically similar but...
4.
Collins K, Stuhlmiller T, Zawistowski J, East M, Pham T, Hall C, et al.
Oncotarget
. 2018 Apr;
9(21):15480-15497.
PMID: 29643987
Multiplexed small molecule inhibitors covalently bound to Sepharose beads (MIBs) were used to capture functional kinases in luminal, HER2-enriched and triple negative (basal-like and claudin-low) breast cancer cell lines and...
5.
Zawistowski J, Goulet D, Johnson G
Cell Cycle
. 2017 Mar;
16(8):731-732.
PMID: 28287892
No abstract available.
6.
Zawistowski J, Bevill S, Goulet D, Stuhlmiller T, Beltran A, Olivares-Quintero J, et al.
Cancer Discov
. 2017 Jan;
7(3):302-321.
PMID: 28108460
Targeting the dysregulated BRAF-MEK-ERK pathway in cancer has increasingly emerged in clinical trial design. Despite clinical responses in specific cancers using inhibitors targeting BRAF and MEK, resistance develops often involving...
7.
Miller S, Goulet D, Johnson G
J Cell Physiol
. 2016 May;
232(1):53-60.
PMID: 27186656
Protein kinases are highly tractable targets for the treatment of many cancers including breast cancer, due to their essential role in tumor cell proliferation and survival. Sequencing of the breast...
8.
Goulet D, Knee K, King J
Exp Eye Res
. 2011 May;
93(4):371-81.
PMID: 21600897
Cataract affects 1 in 6 Americans over the age of 40, and represents a global health problem. Mature onset cataract is associated with the aggregation of partially unfolded or damaged...
9.
Knee K, Goulet D, Zhang J, Chen B, Chiu W, King J
Protein Sci
. 2010 Oct;
20(1):30-41.
PMID: 20981710
Chaperonins assist in the folding of nascent and misfolded proteins, though the mechanism of folding within the lumen of the chaperonin remains poorly understood. The archeal chaperonin from Methanococcus marapaludis,...
10.
Pereira J, Ralston C, Douglas N, Meyer D, Knee K, Goulet D, et al.
J Biol Chem
. 2010 Jun;
285(36):27958-66.
PMID: 20573955
Chaperonins are large protein complexes consisting of two stacked multisubunit rings, which open and close in an ATP-dependent manner to create a protected environment for protein folding. Here, we describe...